[go: up one dir, main page]

PE20120649A1 - Suspensiones acuosas de riluzol - Google Patents

Suspensiones acuosas de riluzol

Info

Publication number
PE20120649A1
PE20120649A1 PE2011001558A PE2011001558A PE20120649A1 PE 20120649 A1 PE20120649 A1 PE 20120649A1 PE 2011001558 A PE2011001558 A PE 2011001558A PE 2011001558 A PE2011001558 A PE 2011001558A PE 20120649 A1 PE20120649 A1 PE 20120649A1
Authority
PE
Peru
Prior art keywords
ionic
riluzole
agar
gum
volume
Prior art date
Application number
PE2011001558A
Other languages
English (en)
Inventor
Roberta Artico
Marco Adami
Daniele Barbareschi
Jaime Moscoso
Tiziano Oldoni
Paolo Mascagni
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120649(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of PE20120649A1 publication Critical patent/PE20120649A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UNA SUSPENCION ACUOSA QUE COMPRENDE: (I) RILUZOL EN FORMA DE PARTICULAS Y CUYO TAMANO PROMEDIO ES MENOR DE 200 MICRAS Y ESTA PRESENTE EN CANTIDADES MENORES A 1.0% PESO/VOLUMEN; (II) UN SURFACTANTE SELECIONADO ENTRE IONICOS, ANIONICOS Y NO IONICOS TALES COMO CARBOXILATOS, EMULGENTES NATURALES, ESTERES DE ACIDO SULFURICO, SLUFONATOS Y/O ETERES NO IONICOS Y ESTA PRESENTE EN CANTIDADES DESDE 0.005% HASTA 2% PESO/VOLUMEN; (III) UN AGENTE DE SUSPENSION SELECCIONADO ENTRE ARCILLAS ESMECTITAS TAL COMO SILICATO DE ALUMINIO MAGNESIO, GOMAS NATURALES TALES COMO GOMA XANTANA, GOMA TRAGACANTO, GOMA GUAR, AGAR-AGAR, ALGINATOS, CELULOSA MICROCRISTALINA O UNA MEZCLA DE LOS MISMOS. DICHA SUSPENSION ES ESTABLE Y CON EFECTO ANESTESICO MINIMO O NULO EN LA BOCA SIENDO UTIL EN EL TRATAMIENTO DE LA ESCLEROSIS LATERAL AMIOTROFICA (ELA)
PE2011001558A 2009-03-13 2010-03-02 Suspensiones acuosas de riluzol PE20120649A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09425101A EP2228054A1 (en) 2009-03-13 2009-03-13 Riluzole aqueous suspensions

Publications (1)

Publication Number Publication Date
PE20120649A1 true PE20120649A1 (es) 2012-06-07

Family

ID=40810549

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001558A PE20120649A1 (es) 2009-03-13 2010-03-02 Suspensiones acuosas de riluzol

Country Status (22)

Country Link
US (1) US8765150B2 (es)
EP (2) EP2228054A1 (es)
JP (1) JP5607083B2 (es)
KR (1) KR101680175B1 (es)
CN (1) CN102341091B (es)
BR (1) BRPI1006418A2 (es)
CA (1) CA2748856C (es)
CL (1) CL2011002217A1 (es)
CO (1) CO6410281A2 (es)
CY (1) CY1113825T1 (es)
DK (1) DK2405890T3 (es)
ES (1) ES2400349T3 (es)
HK (1) HK1161985A1 (es)
HR (1) HRP20130021T1 (es)
MX (1) MX2011008922A (es)
PE (1) PE20120649A1 (es)
PL (1) PL2405890T3 (es)
PT (1) PT2405890E (es)
RU (1) RU2498802C2 (es)
SI (1) SI2405890T1 (es)
SM (1) SMT201300022B (es)
WO (1) WO2010102923A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272082B2 (en) * 2011-07-13 2019-04-30 Cytokinetics, Inc. Combination ALS therapy
US10357497B2 (en) * 2012-06-23 2019-07-23 Biohaven Pharmaceutical Holding Company Limited Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
ES2644840T3 (es) * 2014-11-20 2017-11-30 S.I.I.T. S.R.L.-Servizio Internazionale Imballaggi Termosaldanti Preparación medicinal a base de diosmectita
KR20230135183A (ko) 2014-11-21 2023-09-22 바이오하벤 파마슈티컬 홀딩 컴퍼니 엘티디. 릴루졸의 설하 제제
CN107735077A (zh) * 2014-11-21 2018-02-23 拜尔哈文制药股份有限公司 利鲁唑的舌下给药
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
CN105726477B (zh) * 2016-03-01 2018-10-12 山东司邦得制药有限公司 一种小儿多潘立酮混悬液及其制备方法
CN108721325B (zh) * 2017-04-13 2020-03-06 辽宁大熊制药有限公司 蒙脱石混悬液及其制备方法
WO2019108594A1 (en) * 2017-11-28 2019-06-06 University Of Houston System Liquid formulations of riluzole for oral and intravenous use
CN111437256A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 一种利鲁唑缓释口服混悬液
CN115025056A (zh) * 2022-06-27 2022-09-09 郑州大学第一附属医院 一种含有替加氟、吉莫斯特和奥替拉西钾的口腔崩解制剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ288492B6 (en) 1990-04-24 2001-06-13 Biota Scient Management Derivatives of alpha-D-neuraminic acid, process of their preparation, their use and pharmaceutical preparations based thereon
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CA2375874A1 (en) * 1999-06-04 2000-12-14 Chris Polman Use of riluzole for the treatment of multiple sclerosis
KR20020029098A (ko) 1999-08-12 2002-04-17 피터 지. 스트링거 외부기생충박멸용 스피노신의 수성 현탁액 제제
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6432992B1 (en) 2000-06-05 2002-08-13 Aventis Pharm Sa Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
EP1567152B1 (en) 2002-11-15 2013-08-14 Teva Pharmaceutical Industries Limited Use of rasagiline with riluzole to treat amyotrophic lateral sclerosis
EP1477166B1 (de) * 2003-04-28 2006-08-23 Biofrontera Bioscience GmbH Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
US9492541B2 (en) 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
AU2005218625A1 (en) 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
ITMI20061274A1 (it) 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
US9132071B2 (en) * 2006-07-28 2015-09-15 Santen Sas Compositions containing quaternary ammonium compounds
UA41879U (ru) * 2009-02-03 2009-06-10 Сергей Викторович Фурс Инфракрасный обогревательный прибор

Also Published As

Publication number Publication date
EP2405890B1 (en) 2012-11-28
PL2405890T3 (pl) 2013-04-30
RU2498802C2 (ru) 2013-11-20
KR20120003854A (ko) 2012-01-11
BRPI1006418A2 (pt) 2016-11-29
DK2405890T3 (da) 2013-02-04
MX2011008922A (es) 2011-12-06
HRP20130021T1 (hr) 2013-02-28
WO2010102923A2 (en) 2010-09-16
CY1113825T1 (el) 2016-07-27
EP2405890A2 (en) 2012-01-18
JP2012520254A (ja) 2012-09-06
CA2748856A1 (en) 2010-09-16
CN102341091A (zh) 2012-02-01
SI2405890T1 (sl) 2013-02-28
HK1161985A1 (en) 2012-08-17
WO2010102923A3 (en) 2011-03-03
US8765150B2 (en) 2014-07-01
KR101680175B1 (ko) 2016-11-28
CL2011002217A1 (es) 2012-03-09
US20120039953A1 (en) 2012-02-16
EP2228054A1 (en) 2010-09-15
PT2405890E (pt) 2013-02-20
CO6410281A2 (es) 2012-03-30
ES2400349T3 (es) 2013-04-09
CN102341091B (zh) 2013-08-07
SMT201300022B (it) 2013-03-08
JP5607083B2 (ja) 2014-10-15
CA2748856C (en) 2017-01-03
RU2011141422A (ru) 2013-04-20

Similar Documents

Publication Publication Date Title
PE20120649A1 (es) Suspensiones acuosas de riluzol
MX2017006335A (es) Composiciones en gel de oxido de metal quelado.
BR112014012981A2 (pt) degradação eletrolítica controlada de ferramentas de fundo de poço
ATE528992T1 (de) Verwendung eines desinfektionsmittels auf der basis wässriger, hypochlorige säure (hocl) enthaltender lösungen
AR094012A1 (es) Composiciones estables con peroxido para el cuidado oral
AR098773A1 (es) Composiciones para cuidado oral que comprenden carbonato de calcio y arcilla
BR112015009568A2 (pt) composição de hipoclorito de sódio, e, método de transportar hipoclorito de sódio
EP2295384A4 (en) GLASS COMPOSITION FOR COLOR-SENSITIZED SOLAR CELL AND MATERIAL FOR COLOR-SENSITIZED SOLAR CELL
UY33006A (es) Composicion con sistema de suspension estable
AR099201A1 (es) Composiciones de limpieza que contienen plata estable
CN100530807C (zh) 固态胶状铅蓄电池电解液
CN102041181A (zh) 厕所除垢剂
MX2013015273A (es) Solucion oftalmica que contiene acido hialuronico o sal del mismo y propilenglicol.
CN103120186A (zh) 环保餐具消毒剂
CN102399641A (zh) 原羊毛洗涤剂
CN202308575U (zh) 一种插座
CN202611036U (zh) 隐框玻璃幕墙玻璃托条
CN103710165A (zh) 一种机动车玻璃清洁剂
CN103725426A (zh) 一种医用抗菌清洁剂
CN102400345A (zh) 蚕丝织物精炼液
CN101928553A (zh) 冰敷蓄冷剂
CN102398929A (zh) 高性能水质稳定剂
CN102040983A (zh) 泡沫堵水液
CN104673517A (zh) 一种双效洗衣液
UA87395U (uk) Спосіб приготування тампонажного розчину

Legal Events

Date Code Title Description
FG Grant, registration